Eikon Therapeutics Inc.
Eikon Therapeutics Inc. (EIKN): 10 pipeline candidates · 2 upcoming catalysts · ~17 mo cash runway · 10 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
16.7 months
D/E 0.55 · 0% dilution
Lead: Phase 2/Phase 3
10 candidates
2 upcoming, next in ~5280d
9 buys · 0 sells (180d)
A transparent, data-derived signal for Eikon Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$486.2M
Cash
$161.2M
Quarterly Burn
$89.8M
Runway
16.7 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (10 candidates)
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
47
Total value held
$174.0M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 3,836,830 | $40.6M |
| blackrock, inc. | 3,319,379 | $35.1M |
| vanguard capital management llc | 1,938,862 | $20.5M |
| alliancebernstein l.p. | 1,022,188 | $10.8M |
| ecor1 capital, llc | 732,606 | $7.8M |
| baker bros. advisors lp | 555,555 | $5.9M |
| soros capital management llc | 484,672 | $5.1M |
| stepstone group lp | 395,340 | $4.2M |
| canada pension plan investment board | 379,024 | $4.0M |
| franklin resources inc | 350,000 | $3.7M |
Showing top 10 of 47 institutional holders of Eikon Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Eikon Therapeutics Inc.'s pipeline?
Eikon Therapeutics Inc. (EIKN) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Eikon Therapeutics Inc.'s lead drug candidate?
Eikon Therapeutics Inc.'s most advanced tracked candidate is bdb001 (Phase 2) for Tumor, Solid.
What is Eikon Therapeutics Inc.'s next catalyst?
Eikon Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to E" — expected December 1, 2040.
What is Eikon Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Eikon Therapeutics Inc. has approximately 16.7 months of cash runway.
What is Eikon Therapeutics Inc.'s market capitalization?
Eikon Therapeutics Inc.'s market capitalization is approximately $486.2M.
Get the full picture on Eikon Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.